BusinessPeregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)By Nasdaq OMXJan 5, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Biotech Showcase 2018By Nasdaq OMXJan 2, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive OfficerBy Nasdaq OMXDec 26, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXDec 11, 2017, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017By Nasdaq OMXDec 4, 2017, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 19, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
